Developer docs
API playgroundTry for free, no card

Search company profiles

FimmCyte

Full company profile

uuid00031kq

Namestring
FimmCyte
Legal namestring
FimmCyte AG
Websiteurl
fimmcyte.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

FimmCyte AG is a Swiss pre-clinical biotechnology company headquartered in Basel with a secondary office in Copenhagen, founded in 2022 as a spin-off from the University of Zurich and University Hospital Zurich by Valentina Vongrad (CSO) and Mohaned Shilaih (CEO). The company develops a proprietary antibody immunotherapy platform that targets a specific protein overexpressed in diseased cells, enabling precise elimination of fibrotic tissue while preserving healthy areas. Its lead candidate, FMC2, is a first-in-class, non-hormonal, disease-modifying antibody treatment for endometriosis designed to address the root pathology rather than symptoms, with additional pipeline assets FMC3 and FMC4 extending the platform to other chronic fibro-inflammatory indications such as organ, kidney, and heart fibrosis.

The company serves an underserved patient population — approximately 190 million women globally are affected by endometriosis, where existing treatments are limited to hormonal therapies and surgery with significant side effects — and serves pharmaceutical partners as its commercial counterparties. FimmCyte's business model is structured around licensing and milestone payments rather than direct product sales: it pursues non-dilutive institutional funding (Venture Kick, UZH Life Sciences Fund, BioInnovation Institute, Innosuisse, Gebert Rüf, BaseLaunch, InnoBooster) for R&D while monetizing through strategic pharma partnerships such as the February 2026 Gedeon Richter option-to-license agreement granting exclusive global development and commercialization rights to FMC2.

As a pre-clinical stage company with 1-10 employees, FimmCyte has no current product revenue. Its go-to-market is conducted through biotech partnering events (e.g., BIO-Europe Spring), scientific publications, and direct outreach to pharmaceutical partners, with leadership combining scientific founders and senior pharma executives (Chairman Dr. Markus Kalousek, ex-Novartis VP Partnering; CMO Dr. Maureen Cronin, former Bayer VP Women's Health and Vifor EVP) to support both R&D and eventual commercialization.

Short descriptiontext

FimmCyte AG is a Swiss pre-clinical biotech developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases, with lead candidate FMC2 — a first-in-class non-hormonal, disease-modifying treatment for endometriosis — licensed to Gedeon Richter for global development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody immunotherapy platform, endometriosis treatment development, fibro-inflammatory disease therapy, preclinical biotech pipeline, non-hormonal therapeutic development
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

FimmCyte is a pre-clinical stage biotech with no current revenue. The company plans to generate revenue through licensing agreements with pharmaceutical partners, receiving development and commercial milestone payments along with tiered royalties on net sales. The Gedeon Richter agreement includes pre-agreed terms for milestone payments and royalties.

fimmcyte.com
2Non-dilutive funding and grants
TypeManaged Services
Description

The company has received multiple non-dilutive funding sources including convertible loans from UZH Life Sciences Fund (CHF 1M), BioInnovation Institute (EUR 1.3M), and grants from Venture Kick (CHF 150,000), Innosuisse, and Gebert Rüf Foundation.

fimmcyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

FimmCyte is a pre-clinical biotechnology company developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases. Its lead candidate, FMC2, is a first-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis by targeting a well-established fibrosis marker. The pipeline extends to FMC3 and FMC4 for additional fibro-inflammatory indications, with all assets built on the same proprietary platform that enables precise elimination of diseased tissue while preserving healthy areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Potential to be one of the first disease-modifying treatments for endometriosis, addressing root cause rather than symptoms
Product overview1 text field

FimmCyte is a pre-clinical stage biotech company developing a pipeline of disease-modifying treatments for chronic fibro-inflammatory diseases, primarily focused on women's health. The company's portfolio consists of FMC2 (lead clinical candidate for endometriosis in IND-enabling/clinical candidate ready stage), FMC3 (fibro-inflammatory diseases in lead optimization), and FMC4 (additional pipeline asset). All candidates are built on FimmCyte's proprietary antibody immunotherapy platform, which leverages the discovery of a specific protein marker of fibrosis to enable precise targeting and elimination of diseased tissue while preserving healthy areas. The platform represents a first-in-class, non-hormonal approach to treating endometriosis and other fibro-inflammatory conditions.

Product and service3 records
1FMC2
CategoryTherapeutic antibody candidate (endometriosis)
Description

First-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis through disease-modifying mechanisms. FMC2 recognizes a well-established marker of fibrosis and has demonstrated antifibrotic effects in preclinical studies. Licensed to Gedeon Richter under an exclusive option-to-license agreement covering global rights exercisable prior to first-in-human clinical studies.

2FMC3
CategoryTherapeutic antibody candidate (fibro-inflammatory diseases)
Description

Next-generation antibody therapy in lead optimization stage targeting fibro-inflammatory diseases, extending FimmCyte's proprietary antibody platform beyond endometriosis to additional chronic conditions.

3FMC4
CategoryTherapeutic antibody candidate (fibro-inflammatory diseases)
Description

Additional pipeline antibody asset for chronic fibro-inflammatory diseases, part of FimmCyte's portfolio of next-generation therapies designed to transform patient care by providing effective, targeted treatments.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter, a leading Hungarian pharmaceutical company with EUR 2.2bn in 2024 sales. Both companies will conduct joint R&D toward first-in-human clinical studies for FMC2. Gedeon Richter holds an exclusive option on global rights exercisable before first clinical trial initiation. FimmCyte is eligible to receive development and commercial milestone payments along with tiered royalties on net sales under pre-agreed terms.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Healthcare accelerator supporting FimmCyte through its biotech ecosystem, providing funding and development support.

Strategic tierCoreTypeTechnology or Integration
Description

Academic partner and founding institution of FimmCyte spin-off, providing research capabilities and clinical expertise.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage biotech developing pamrevlumab (anti-CTGF antibody) for fibrotic diseases including IPF and pancreatic cancer. Broad incumbent with a directly comparable monoclonal antibody approach to fibrosis, a key mechanism aligned with FimmCyte's anti-fibrotic platform.

TypeDirect peer
Description

Swiss-based clinical-stage women's health biotech historically focused on endometriosis (linzagolix) and uterine fibroids. Direct peer as a small-cap, Swiss-headquartered biotech developing novel therapeutics for endometriosis, although ObsEva has faced significant restructuring.

TypeBroad incumbent
Description

Private global pharmaceutical company specializing in reproductive health, women's health, and gastroenterology, with a meaningful endometriosis therapeutic franchise. Broad incumbent in women's health and a potential strategic partner comparable to Gedeon Richter for FimmCyte's FMC2 development.

TypeDirect peer
Description

Women's health-focused biotech (now part of Sumitomo Pharma) that developed relugolix, approved for endometriosis and uterine fibroids. Directly comparable as a focused women's health therapeutic company targeting endometriosis, representing the most advanced commercial-stage competitor to FimmCyte's FMC2.

TypeBroad incumbent
Description

Women's health-focused pharmaceutical spinoff from Merck with established endometriosis and uterine fibroid products. Broad incumbent in women's health therapeutics with the commercial infrastructure and provider relationships that FimmCyte would need to access for any direct commercialization.

TypeDirect peer
Description

Clinical-stage biotech developing antibody-based therapies for fibrosis, with an integrin-targeting platform addressing fibro-inflammatory diseases. Directly comparable to FimmCyte's antibody immunotherapy approach for fibro-inflammatory indications, including organ fibrosis targets that overlap with FimmCyte's FMC3/FMC4 pipeline expansion ambitions.

TypeBroad incumbent
Description

Global pharmaceutical company with the leading endometriosis franchise (Orilissa/elagolix, Oriahnn) and a broader women's health portfolio. Broad incumbent in the endometriosis therapeutic area against which FimmCyte's FMC2 would compete commercially if approved.

TypeBroad incumbent
Description

European biotech with a historical fibrosis pipeline including ziritaxestat and other IPF candidates, and an active push into immunology. Broad incumbent in the fibro-inflammatory space relevant to FimmCyte's platform expansion strategy.

TypeBroad incumbent
Description

Global pharmaceutical company with a significant women's health franchise including Visanne (dienogest) for endometriosis. Broad incumbent with established commercial infrastructure in endometriosis that FimmCyte's CMO Dr. Cronin helped build during her tenure as VP of Women's Health at Bayer.

10Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company with a leading fibrosis franchise, including nintedanib (Ofev) approved for idiopathic pulmonary fibrosis and other fibrotic diseases. Broad incumbent in the broader fibro-inflammatory space where FimmCyte's platform could expand beyond endometriosis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FimmCyte

Biopharmaceuticalsfimmcyte.com

FimmCyte AG is a Swiss pre-clinical biotech developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases, with lead candidate FMC2 — a first-in-class non-hormonal, disease-modifying treatment for endometriosis — licensed to Gedeon Richter for global development.

What FimmCyte does

FimmCyte AG is a Swiss pre-clinical biotechnology company headquartered in Basel with a secondary office in Copenhagen, founded in 2022 as a spin-off from the University of Zurich and University Hospital Zurich by Valentina Vongrad (CSO) and Mohaned Shilaih (CEO). The company develops a proprietary antibody immunotherapy platform that targets a specific protein overexpressed in diseased cells, enabling precise elimination of fibrotic tissue while preserving healthy areas. Its lead candidate, FMC2, is a first-in-class, non-hormonal, disease-modifying antibody treatment for endometriosis designed to address the root pathology rather than symptoms, with additional pipeline assets FMC3 and FMC4 extending the platform to other chronic fibro-inflammatory indications such as organ, kidney, and heart fibrosis.

The company serves an underserved patient population — approximately 190 million women globally are affected by endometriosis, where existing treatments are limited to hormonal therapies and surgery with significant side effects — and serves pharmaceutical partners as its commercial counterparties. FimmCyte's business model is structured around licensing and milestone payments rather than direct product sales: it pursues non-dilutive institutional funding (Venture Kick, UZH Life Sciences Fund, BioInnovation Institute, Innosuisse, Gebert Rüf, BaseLaunch, InnoBooster) for R&D while monetizing through strategic pharma partnerships such as the February 2026 Gedeon Richter option-to-license agreement granting exclusive global development and commercialization rights to FMC2.

As a pre-clinical stage company with 1-10 employees, FimmCyte has no current product revenue. Its go-to-market is conducted through biotech partnering events (e.g., BIO-Europe Spring), scientific publications, and direct outreach to pharmaceutical partners, with leadership combining scientific founders and senior pharma executives (Chairman Dr. Markus Kalousek, ex-Novartis VP Partnering; CMO Dr. Maureen Cronin, former Bayer VP Women's Health and Vifor EVP) to support both R&D and eventual commercialization.

FimmCyte firmographics

Firmographics
Name
FimmCyte
Legal name
FimmCyte AG
Website
https://fimmcyte.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
FimmCyte AG is a Swiss pre-clinical biotech developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases, with lead candidate FMC2 — a first-in-class non-hormonal, disease-modifying treatment for endometriosis — licensed to Gedeon Richter for global development.
Ownership category
akta.pro rank

FimmCyte industry classification

Industry
Product category
Biopharmaceuticals
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody immunotherapy platform
  • Endometriosis treatment development
  • Fibro-inflammatory disease therapy
  • Preclinical biotech pipeline
  • Non-hormonal therapeutic development

Where FimmCyte is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

FimmCyte business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing and milestone payments: FimmCyte is a pre-clinical stage biotech with no current revenue. The company plans to generate revenue through licensing agreements with pharmaceutical partners, receiving development and commercial milestone payments along with tiered royalties on net sales. The Gedeon Richter agreement includes pre-agreed terms for milestone payments and royalties.
  2. Non-dilutive funding and grants: The company has received multiple non-dilutive funding sources including convertible loans from UZH Life Sciences Fund (CHF 1M), BioInnovation Institute (EUR 1.3M), and grants from Venture Kick (CHF 150,000), Innosuisse, and Gebert Rüf Foundation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

FimmCyte product offering

Product offering

Core offering

FimmCyte is a pre-clinical biotechnology company developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases. Its lead candidate, FMC2, is a first-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis by targeting a well-established fibrosis marker. The pipeline extends to FMC3 and FMC4 for additional fibro-inflammatory indications, with all assets built on the same proprietary platform that enables precise elimination of diseased tissue while preserving healthy areas.

Product overview

FimmCyte is a pre-clinical stage biotech company developing a pipeline of disease-modifying treatments for chronic fibro-inflammatory diseases, primarily focused on women's health. The company's portfolio consists of FMC2 (lead clinical candidate for endometriosis in IND-enabling/clinical candidate ready stage), FMC3 (fibro-inflammatory diseases in lead optimization), and FMC4 (additional pipeline asset). All candidates are built on FimmCyte's proprietary antibody immunotherapy platform, which leverages the discovery of a specific protein marker of fibrosis to enable precise targeting and elimination of diseased tissue while preserving healthy areas. The platform represents a first-in-class, non-hormonal approach to treating endometriosis and other fibro-inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • FMC2 First-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis through disease-modifying mechanisms. FMC2 recognizes a well-established marker of fibrosis and has demonstrated antifibrotic effects in preclinical studies. Licensed to Gedeon Richter under an exclusive option-to-license agreement covering global rights exercisable prior to first-in-human clinical studies.
  • FMC3 Next-generation antibody therapy in lead optimization stage targeting fibro-inflammatory diseases, extending FimmCyte's proprietary antibody platform beyond endometriosis to additional chronic conditions.
  • FMC4 Additional pipeline antibody asset for chronic fibro-inflammatory diseases, part of FimmCyte's portfolio of next-generation therapies designed to transform patient care by providing effective, targeted treatments.

Quantifiable outcome

  • Potential to be one of the first disease-modifying treatments for endometriosis, addressing root cause rather than symptoms

Companies that use FimmCyte

Customer profile

Segments2 records

Ideal customer profiles2 records

FimmCyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

FimmCyte partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Gedeon RichterflagshipStrategic or Co-development Partner · 18 February 2026FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter, a leading Hungarian pharmaceutical company with EUR 2.2bn in 2024 sales. Both companies will conduct joint R&D toward first-in-human clinical studies for FMC2. Gedeon Richter holds an exclusive option on global rights exercisable before first clinical trial initiation. FimmCyte is eligible to receive development and commercial milestone payments along with tiered royalties on net sales under pre-agreed terms.
  • BaseLaunchcoreStrategic or Co-development PartnerHealthcare accelerator supporting FimmCyte through its biotech ecosystem, providing funding and development support.
  • University Hospital Zurich (USZ)coreTechnology or IntegrationAcademic partner and founding institution of FimmCyte spin-off, providing research capabilities and clinical expertise.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

FimmCyte competitors and assessment

Company assessment

Broad incumbents

  • FibroGen: Clinical-stage biotech developing pamrevlumab (anti-CTGF antibody) for fibrotic diseases including IPF and pancreatic cancer. Broad incumbent with a directly comparable monoclonal antibody approach to fibrosis, a key mechanism aligned with FimmCyte's anti-fibrotic platform.
  • Ferring Pharmaceuticals: Private global pharmaceutical company specializing in reproductive health, women's health, and gastroenterology, with a meaningful endometriosis therapeutic franchise. Broad incumbent in women's health and a potential strategic partner comparable to Gedeon Richter for FimmCyte's FMC2 development.
  • Organon & Co. Women's health-focused pharmaceutical spinoff from Merck with established endometriosis and uterine fibroid products. Broad incumbent in women's health therapeutics with the commercial infrastructure and provider relationships that FimmCyte would need to access for any direct commercialization.
  • AbbVie: Global pharmaceutical company with the leading endometriosis franchise (Orilissa/elagolix, Oriahnn) and a broader women's health portfolio. Broad incumbent in the endometriosis therapeutic area against which FimmCyte's FMC2 would compete commercially if approved.
  • Galapagos NV: European biotech with a historical fibrosis pipeline including ziritaxestat and other IPF candidates, and an active push into immunology. Broad incumbent in the fibro-inflammatory space relevant to FimmCyte's platform expansion strategy.
  • Bayer: Global pharmaceutical company with a significant women's health franchise including Visanne (dienogest) for endometriosis. Broad incumbent with established commercial infrastructure in endometriosis that FimmCyte's CMO Dr. Cronin helped build during her tenure as VP of Women's Health at Bayer.
  • Boehringer Ingelheim: Global pharmaceutical company with a leading fibrosis franchise, including nintedanib (Ofev) approved for idiopathic pulmonary fibrosis and other fibrotic diseases. Broad incumbent in the broader fibro-inflammatory space where FimmCyte's platform could expand beyond endometriosis.

Direct peers

  • ObsEva: Swiss-based clinical-stage women's health biotech historically focused on endometriosis (linzagolix) and uterine fibroids. Direct peer as a small-cap, Swiss-headquartered biotech developing novel therapeutics for endometriosis, although ObsEva has faced significant restructuring.
  • Myovant Sciences (Sumitomo Pharma): Women's health-focused biotech (now part of Sumitomo Pharma) that developed relugolix, approved for endometriosis and uterine fibroids. Directly comparable as a focused women's health therapeutic company targeting endometriosis, representing the most advanced commercial-stage competitor to FimmCyte's FMC2.
  • Pliant Therapeutics: Clinical-stage biotech developing antibody-based therapies for fibrosis, with an integrin-targeting platform addressing fibro-inflammatory diseases. Directly comparable to FimmCyte's antibody immunotherapy approach for fibro-inflammatory indications, including organ fibrosis targets that overlap with FimmCyte's FMC3/FMC4 pipeline expansion ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

FimmCyte social profiles

Digital presence

FimmCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FimmCyte leadership team

Management profile

Number of profiles

Profiles5 records

FimmCyte funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FimmCyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FimmCyte

What does FimmCyte do?

FimmCyte is a pre-clinical biotechnology company developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases. Its lead candidate, FMC2, is a first-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis by targeting a well-established fibrosis marker. The pipeline extends to FMC3 and FMC4 for additional fibro-inflammatory indications, with all assets built on the same proprietary platform that enables precise elimination of diseased tissue while preserving healthy areas.

Is FimmCyte a public or private company?

FimmCyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was FimmCyte founded?

FimmCyte was founded in 2022. It employs 1 to 10 people.

Where is FimmCyte based?

FimmCyte is headquartered in Basel, Switzerland, in the Europe region.

How does FimmCyte make money?

Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are non-dilutive funding and grants.

Who are FimmCyte's main competitors?

Broad incumbents on record are FibroGen, Ferring Pharmaceuticals, Organon & Co., AbbVie, Galapagos NV, Bayer and Boehringer Ingelheim. Direct peers are ObsEva, Myovant Sciences (Sumitomo Pharma) and Pliant Therapeutics.

Does FimmCyte have an API?

No public API is recorded for FimmCyte.

What industry is FimmCyte in?

FimmCyte's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HomepageFimmCyte Partners with Gedeon Richter to Advance Non-Hormonal Endometriosis TreatmentSwiss biotech FimmCyte has entered a strategic research collaboration and option-to-license agreement with Hungarian pharmaceutical company Gedeon Richter to advance its first-in-class, non-hormonal antibody treatment FMC2 for endometriosis. Under the deal, both companies will conduct joint R&D toward first-in-human clinical studies, with Gedeon Richter holding an exclusive option on global rights exercisable before the first clinical trial. The partnership provides FimmCyte with development capabilities and commercialization infrastructure in women's health, addressing a condition affecting roughly 190 million women worldwide with currently limited treatment options beyond hormonal therapies and surgery.startupticker.chFemtech FimmCyte closes wide-ranging agreement with RichterFimmCyte, a femtech biotech spin-off from the University of Zurich founded in 2022, has entered into a strategic research collaboration and option-to-license agreement with Gedeon Richter, a leading Hungarian pharmaceutical company, to advance its lead clinical candidate FMC2 for treating endometriosis. The parties have fully negotiated a definitive exclusive worldwide license agreement for the antibody's development and commercialization, with Richter operating Central Europe's largest R&D hub and reporting EUR 2.2 billion in 2024 sales. FimmCyte will be eligible to receive development and commercial milestone payments along with tiered royalties on net sales under the pre-agreed terms.BaselaunchFimmCyte obtains CHF 1 million from the UZH Life Sciences FundFimmCyte, a women's health biotech, received a CHF 1 million convertible loan from the UZH Life Sciences Fund. The company's advanced program is a non-hormonal disease-modifying treatment for endometriosis, and it is set to advance into IND enabling activities.VenturelabFimmCyte secures 1 million CHF investment for Non-Hormonal Endometriosis treatmentFimmCyte has secured a CHF 1 million convertible loan from the UZH Life Sciences Fund to support the development of its non-hormonal endometriosis treatment. The startup plans to use these funds to advance its flagship project into IND-enabling activities, building on prior support from entities such as BaseLaunch and Innosuisse.startupticker.chFimmCyte obtains CHF 1 million from the UZH Life Sciences FundFimmCyte, a biotech spin-off from the University of Zürich, secured a 1 million CHF convertible loan from the UZH Life Sciences Fund to advance its non-hormonal treatment for endometriosis. This investment serves as a strategic steppingstone for the company as it prepares to initiate IND-enabling activities and raises capital for a subsequent Seed financing round.EIN PresswireFimmCyte announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences FundFimmCyte secured a 1 million CHF convertible loan from the UZH Life Sciences Fund to support the development of its endometriosis treatment. This investment serves as a strategic stepping stone for the biotech company as it prepares to raise seed funding and advance its program into IND-enabling activities. The deal highlights continued institutional backing for the company's novel immune-reprogramming approach in women's health.LinkedInFimmCyte announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences FundFimmCyte secured a 1 million CHF convertible loan from the UZH Life Sciences Fund. This investment serves as a significant vote of confidence in the company's mission to develop disease-modifying treatments for endometriosis. FimmCyte is currently raising its next seed round financing to support IND and FiH stages.Venture KickFimmCyte wins CHF 150,000 to advance their non-hormonal, disease-modifying treatment for endometriosisFimmCyte has received CHF 150,000 to further develop its non-hormonal, disease-modifying treatment for endometriosis. This funding will help advance their lead candidate through preclinical regulatory requirements, paving the way for an initial human trial in the coming years. The startup intends to address the significant market for endometriosis treatments, which is estimated at USD 14 billion annually.startupticker.chNew projects to fast-track progress with InnoboosterThe Gebert Rüf Stiftung awarded CHF 150,000 grants each to three startups—Tune Insight, FimmCyte, and MYLEG—to advance their deep tech projects through the Innobooster program. These funds will support the development of secure machine learning services, novel antibody-based endometriosis treatments, and sensory feedback add-ons for prostheses over the next 1.5 years.